Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 12/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.47 |
| ▸ | GAA | P10253 | 7/20 | 0.47 |
| ▸ | GLA | P06280 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | GFER | P55789 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 7/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.46 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.46 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 5/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25749256 | 0.91 | MEN1 (0.54) | HRH4MAPTALDH1A1KDM4EGAA | |
| SCHEMBL31388533 | 0.82 | MAPT (0.50) | MAPTALDH1A1KDM4EGAAGLA | |
| SCHEMBL5355863 | 0.81 | LMNA (0.63) | HRH4MAPTALDH1A1KDM4EGAA | |
| SCHEMBL5351444 | 0.78 | LMNA (0.63) | MAPTALDH1A1KDM4ESMN1; SMN2NPC1 | |
| SCHEMBL5744080 | 0.76 | NPC1 (0.70) | ALDH1A1KDM4ESMN1; SMN2RAB9ANPC1 | |
| SCHEMBL26240946 | 0.76 | GSK3B (0.54) | MAPTALDH1A1KDM4ESMN1; SMN2RAB9A | |
| SCHEMBL28642016 | 0.75 | NPC1 (0.57) | MAPTKDM4ESMN1; SMN2RAB9ANPC1 | |
| SCHEMBL19329394 | 0.74 | MAPT (0.51) | HRH4MAPTALDH1A1KDM4EGAA | |
| SCHEMBL4577384 | 0.74 | LCK (0.61) | MAPTALDH1A1KDM4ESMN1; SMN2NPC1 | |
| SCHEMBL4399180 | 0.73 | PIN1 (0.66) | HRH4MAPTALDH1A1KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050192328-A1 | Compounds and methods for use thereof in the treatment of viral infections | UAF TECHNOLOGIES AND RESEARCH, LLC (US) | 2005-09-01 | — | — | US | disclosed |
| US-6900235-B1 | Benzimidazole compounds, and pharmaceutical compositions and unit dosages thereof | UAF TECHNOLOGIES AND RESEARCH, LLC (US) | 2005-05-31 | — | — | US | disclosed |
| US-6710065-B1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER OR A VIRAL INFECTION | UAF TECHNOLOGIES AND RESEARCH, LLC | 2004-03-23 | — | — | US | disclosed |
| US-6482843-B1 | Compounds and methods for use thereof in the treatment of cancer or viral infections | THE PROCTER & GAMBLE COMPANY | 2002-11-19 | — | — | US | disclosed |
| US-6423736-B1 | ADMINISTERING BENZIMIDAZOLE COMPOUND | THE PROCTOR & GAMBLE COMPANY | 2002-07-23 | — | — | US | disclosed |
| US-6423735-B1 | ADMINISTERING BENZIMIDAZOLE COMPOUND | THE PROCTER & GAMBLE COMPANY | 2002-07-23 | — | — | US | disclosed |
| US-6420411-B1 | BENZIMIDAZOLE DERIVATIVES USED TO TREAT MELANOMA, LEUKEMIA, AND COLON, BREAST, LUNG, PANCREATIC, OVARIAN, AND PROSTATE CANCER; USED TO TREAT HIV; IMPROVED WATER SOLUBILITY | THE PROCTER & GAMBLE COMPANY | 2002-07-16 | — | — | US | disclosed |
| US-6407131-B1 | 5-CARBONYLOXY-1H-BENZIMIDAZOLE-2-CARBAMATE DERIVATIVES | THE PROCTER & GAMBLE COMPANY | 2002-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192328-A1 | Compounds and methods for use thereof in the treatment of viral infections | PAICS, PIGO, BAD | HRH4 2288/4885MAPT 4587/4885ALDH1A1 260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.